Why is the GSK share price rising?

Shares are up 17% over 30 days as investors price in better growth visibility, steady cash generation, and confidence in upcoming regulatory events. The move above the £20.32 analyst target signals strong momentum. Sustaining it requires timely approvals, solid launch execution, and supportive guidance in quarterly updates.

Is GSK valuation stretched after the rally?

It is tighter versus history and some peers, but not conclusive. Intrinsic models still debate upside because outcomes hinge on FDA decisions and launch execution. If catalysts beat expectations, valuation can hold. If news flow cools or costs rise, multiples may revert toward historical averages and prior ranges.

What is the outlook for the GSK dividend?

The GSK dividend is supported by cash generation. Future growth depends on free cash flow, R&D investment, and balance sheet priorities. Strong approvals and launches would improve visibility, while delays could keep policy conservative. Investors should watch quarterly cash conversion metrics and management commentary on capital allocation.

What could move the GSK share price next?

Major drivers include FDA and European approval decisions, pivotal trial readouts, competitive data, and guidance changes. Updates on margins, launch trajectories, and pricing can also shift sentiment. Clear positive catalysts may support the recent breakout, while delays or weak data could trigger a retracement toward earlier trading levels.

Global Market Insights

GSK.L Stock Today, March 2: Valuation Debate Heats as Shares Rally

ByDanny Kontos March 2, 2026March 2, 2026

The GSK share price has surged 17% in the past month, pushing GSK.L above the £20.32 consensus target. This rally sharpened the GSK valuation debate as some models still show a discount to intrinsic value. UK investors now weigh momentum against execution risks from FDA decisions and pipeline delivery. We break down what could keep the GSK share price supported, where it may stall, and how dividend and cash flow strength fit into the GSK stock forecast today.